Currently, there are 1.26B common shares owned by the public and among those 1.26B shares have been available to trade.
The company’s stock has a 5-day price change of -10.71% and -15.42% over the past three months. CVS shares are trading -37.47% year to date (YTD), with the 12-month market performance down to -34.43% lower. It has a 12-month low price of $49.47 and touched a high of $83.25 over the same period. CVS has an average intraday trading volume of 12.14 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -12.33%, -15.26%, and -19.78% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of CVS Health Corp (NYSE: CVS) shares accounts for 82.23% of the company’s 1.26B shares outstanding.
It has a market capitalization of $61.86B and a beta (3y monthly) value of 0.55. The stock’s trailing 12-month PE ratio is 12.54, while the earnings-per-share (ttm) stands at $3.94. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.14% over the week and 3.09% over the month.
Earnings per share for the fiscal year are expected to decrease by -39.11%, and 16.83% over the next financial year.
Looking at the support for the CVS, a number of firms have released research notes about the stock. Deutsche Bank stated their Buy rating for the stock in a research note on December 03, 2024, with the firm’s price target at $66. Wells Fargo coverage for the CVS Health Corp (CVS) stock in a research note released on November 18, 2024 offered a Overweight rating with a price target of $66. Barclays was of a view on October 10, 2024 that the stock is Overweight, while TD Cowen gave the stock Buy rating on October 04, 2024, issuing a price target of $59- $85. Robert W. Baird on their part issued Neutral rating on May 30, 2024.
